Investor Relations

Announcements and Notices

Performance Report

Investor Relations

Hunan Xianshi Pharmaceutical Recognized as 2023 Changsha Municipal Enterprise Technology Center

CHANGSHA, Feb 18, 2024 — Hunan Xianshi Pharmaceutical Co., Ltd. has been officially accredited as a municipal-level Enterprise Technology Center under Changsha’s 2023 annual recognition program.

2024

02-18

Pooling resources to tackle tough challenges! A wave of high-quality projects is set to be completed and put into operation.

As the autumn winds rise and the weather grows cooler, project construction has entered its prime phase. To accelerate project development and ensure early commissioning, on the morning of August 25, Zheng Yiren, Secretary of the Party Working Committee, led a team to conduct field visits to six projects—Zhong’an Bio, Weierman, Zhongnong Xilong, Runxing Pharmaceutical, Xianshi Pharmaceutical, and Zhongyi Gas. He emphasized that today’s projects will become tomorrow’s industries, and that time equates to efficiency. With the onset of cooler weather, all relevant functional departments must strengthen their support services, while each project entity, while prioritizing safe construction, should enhance coordination and expedite progress to ensure timely production and full operational effectiveness. Chen Xunwu, a member of the Party Working Committee and Deputy Director of the Management Committee, also participated in the inspection.

2023

08-25

An industrial policy, infused with deep passion for industry.

Changsha Evening News, Changsha in Hand, February 18 (All‑media reporter Wu Ling, correspondents Li Yanling and Zhou Ying): On the 16th, at the Liuyang Economic Development Zone’s conference on fully implementing the spirit of the 20th National Congress of the Communist Party of China, accelerating high‑quality development, and reviewing the 2023 economic work, four major policies benefiting enterprises were unveiled. Among them, the “Several Policies on Accelerating the High‑Quality Development of the Biopharmaceutical Industry” (hereinafter referred to as the “Several Policies”) marks the first time in the zone’s history that a comprehensive, systematic set of industrial support measures has been formulated for a single sector.

2023

02-22

< 123 >